Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
暂无分享,去创建一个
C. Bloomfield | J. Byrd | S. Patil | R. Mayer | A. Carroll | D. Arthur | F. Davey | C. Schiffer | D. Arthur | D. Lawrence | R. Tantravahi | M. Pettenati | C A Schiffer | M J Pettenati | C D Bloomfield | D Lawrence | J C Byrd | A Carroll | R Tantravahi | S R Patil | F R Davey | D T Berg | D C Arthur | R J Mayer | David S. Lawrence | D. Berg | A. Carroll | R. J. Mayer
[1] H. Skipper,et al. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.
[2] C. Bloomfield,et al. Acute leukemias with structurally altered core binding factor subunits (t(8;21), inv(16), t(12;21)), 27-28 June 1997, Rotterdam, The Netherlands. , 1997, Leukemia.
[3] E. Thiel,et al. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. , 1991, Seminars in hematology.
[4] M. Stul,et al. Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings. , 1995, Blood.
[5] C. Bloomfield,et al. The clinical significance of karyotype in acute myelogenous leukemia. , 1989, Cancer genetics and cytogenetics.
[6] V. Farewell. A model for a binary variable with time-censored observations , 1977 .
[7] Ross Maller,et al. Estimating the proportion of immunes in a censored sample , 1992 .
[8] J Halpern,et al. Cure rate models: power of the logrank and generalized Wilcoxon tests. , 1987, Statistics in medicine.
[9] G. Papa,et al. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). , 1994, Blood.
[10] A I Goldman,et al. Survivorship analysis when cure is a possibility: a Monte Carlo study. , 1984, Statistics in medicine.
[11] F. Mandelli,et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.
[12] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[13] R. Mayer,et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.
[14] M. Caligiuri,et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. , 1998, Cancer research.
[15] M. Freedman,et al. Fusion Between Transcription Factor CBFP/PEBP2I3 andaMyosin HeavyChain in AcuteMyeloid Leukemia , 1993 .
[16] C. Bloomfield,et al. Clinical significance of cytogenetics in acute myeloid leukemia. , 1997, Seminars in oncology.
[17] Edward J. Lee,et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. , 1997, Blood.
[18] E. Estey,et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. , 1995, Leukemia.
[19] F. Collins,et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. , 1993, Science.
[20] J. Rowley,et al. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. , 1982, Blood.
[21] D. Davey,et al. 8;21 translocation in acute nonlymphocytic leukemia. Occurrence in M1 and M2 FAB subtypes. , 1989, American journal of clinical pathology.
[22] S. Vollset,et al. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Tribalto,et al. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. , 1993, Cancer genetics and cytogenetics.
[24] M. Grever,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. , 1996, Blood.
[25] J. Fay,et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Ohki,et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[27] Edward J. Lee,et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.
[28] V. Farewell,et al. The use of mixture models for the analysis of survival data with long-term survivors. , 1982, Biometrics.
[29] G. Tricot,et al. 8/21 translocation in acute myeloid leukaemia. , 2009, Scandinavian journal of haematology.
[30] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .